WHO declares India has eliminated Trachoma as a public health problem in 2024

WHO estimates suggest that 150 million people worldwide are affected by Trachoma

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

JB Pharma buys opthalmology brands from Novartis for Rs 964 Cr

JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

PNB Housing and PVRI launch Pehel Eye Mitra to deliver free transport services to eye patients

50%+ patients delay cataract surgeries in India: Survey

73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries

ENTOD Pharmaceuticals gets DCGI nod to carry out the phase 3 trials of 0.05% atropine eye drops

Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children